Skip to content

Clinical Study on the Treatment of Primary Dysmenorrhea of Qi Stagnation and Blood Stasis Type with Chigao Gao Mo Based on rs-fMRI Observation

Clinical Study on the Treatment of Primary Dysmenorrhea of Qi Stagnation and Blood Stasis Type with Chigao Gao Mo Based on rs-fMRI Observation

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000528
Enrollment
Unknown
Registered
2025-03-14
Start date
2024-08-16
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary dysmenorrhea

Interventions

Treatment group:Gao Mo with Chigao

Sponsors

Jiangsu Province Hospital of TCM
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1. Those who meet the diagnostic criteria for primary dysmenorrhea and the TCM syndrome differentiation criteria for qi stagnation and blood stasis. 2. Age between 18 and 35 years old. 3. The menstrual cycle is generally normal (28 ± 7 days). 4. The average VAS pain score in the past three menstrual cycles is = 4cm. 5. Informed consent and voluntary participation. The process of obtaining informed consent should comply with GCP regulations.

Exclusion criteria

Exclusion criteria: 1. Age under 18 years old or over 35 years old. 2. Secondary dysmenorrhea caused by pelvic inflammatory disease, endometriosis, uterine fibroids, or other factors. 3. Irregular menstrual cycle. 4. Traditional Chinese medicine syndrome differentiation does not belong to the Qi stagnation and blood stasis type. 5. MRI contraindications (claustrophobia, pacemaker implantation, or internal surgical metal plates, etc.). 6. Patients with severe primary diseases such as cardiovascular, liver, kidney, digestive system, etc; Disabled patients as defined by law (blind, deaf, mute, intellectually disabled, mentally disabled, physically disabled). Patients who have taken oral prostaglandin synthase inhibitors within 4 weeks prior to enrollment. According to the researcher's judgment, other lesions that may reduce the likelihood of inclusion or complicate inclusion, such as frequent changes in the work environment, can easily lead to loss to follow-up. 9. Allergic constitution, such as a history of allergies to two or more drugs or foods; Or those who are known to be allergic to the ingredients of this medication. 10. Patients who are currently participating in clinical trials of other drugs. 11. Pregnant, preparing for pregnancy or breastfeeding women.

Design outcomes

Primary

MeasureTime frame
COX Dysmenorrhea Symptom Scale;VAS;Evaluation of Traditional Chinese Medicine Syndrome Efficacy;

Secondary

MeasureTime frame
rs-fMRI;PGF2a;

Countries

China

Contacts

Public ContactZhenkun Xiong

Jiangsu Province Hospital of TCM

xzk8748xy@163.com18066105850

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026